Sign up online today & collaborate
or click here to find out more
Oxford, UK – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy andth abstract
Rates of clinical cure at the end of treatment in the Phase 2 CoDIFy trial were 77.8% for ridinilazole and 69.7% for vancomycin. These analyses were conducted on the modified intent-to-treat (‘mITT’) population that comprised subjects with CDI diagnosed by the presence of free toxin in faeces.
The related poster, entitled “Ridinilazole for
|Company||Summit Therapeutics plc|